Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study

Abstract

BackgroundWe conducted a retrospective analysis to investigate treatment results and prognostic factors of pediatric neuroblastoma patients.MethodsThis retrospective study was carried out analyzing the medical records of patients with the pathological diagnosis of neuroblastoma seen at South Egypt Cancer Institute, Assiut University during the period from January 2001 and January 2010. After induction chemotherapy, response according to international neuoblastoma response criteria was assessed. Radiotherapy to patients with residual primary tumor was applied. Overall and event free survival (OAS and EFS) rates were estimated using Graphed prism program. The Log-rank test was used to examine differences in OAS and EFS rates. Cox-regression multivariate analysis was done to determine the independent prognostic factors affecting survival rates.ResultsFifty three cases were analyzed. The median follow-up duration was 32 months and ranged from 2 to 84 months. The 3-year OAS and EFS rates were 39.4% and 29.3% respectively. Poor prognostic factors included age >1 year of age, N-MYC amplification, and high risk group. The majority of patients (68%) presented in high risk group, where treatment outcome was poor, as only 21% of patients survived for 3 year.ConclusionMultivariate analysis confirmed only the association between survival and risk group. However, in univariate analysis, local radiation therapy resulted in significant survival improvement. Therefore, radiotherapy should be given to patients with residual tumor evident after induction chemotherapy and surgery. Future attempts to improve OAS in high risk group patients with aggressive chemotherapy and bone marrow transplantation should be considered.

Multidisciplinary management of cervical neuroblastoma in infants

“…Amplification of the MYCN oncogene, first described in NB patient in 1983 was one of the first genes shown to be of prognostic value in pediatric oncology and MYCN-amplification maintains its relevance as a marker of high-risk disease for patients with loco regional NB. Besides this, age more than one year, disseminated disease, 1p deletion, 17q25 duplication, di-, or tetraploid DNA content of tumor cells, elevated blood level of LDH and NSE are also unfavorable prognostic factors [1,2,[7][8][9].…”

“…While in the staging of the disease the mIBG (metaiodobenzylguanidine) scintigraphy is available [1,8,9].…”

Neuroblastoma: morphological pattern, molecular genetic features, and prognostic factors

“…На-ряду с параметрами клинического характера (возраст пациента [22], распространение и локализация опухо-ли [7,23]) многообещающими оказались гистологи-ческие (гистопатологическая классификация по си стеме Н. Shimada [20], количество клеток с митозом [24] и апоптозом), молекулярно-биохимические (плоид-ность [25, 26]) и генетические (хромосомные аберра-ции, статус гена MYCN, делеция локусов 1р36 и 11q, увеличение длинного плеча хромосомы 17 и др.) ха-рактеристики опухолевых клеток [17,[27][28][29].…”

Pain and quality of life in patients undergoing radiotherapy for spinal metastatic disease treatment

“…Radiotherapy is an important tool for the control of pain and local neoplastic progression. Several studies have demonstrated its efficacy in stabilizing the progression of pain and in maintaining the ability of the patient to walk, which are considered import goals of treatment [3-6]. …”